The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Biopharmaceutical CROs Market: Distribution by Type of Biologic (Vaccines, Cell Therapy, Gene Therapy, Antibodies, Recombinant Proteins / Peptides, and Others), Scale of Operation (Clinical and Preclinical), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, and Other Therapeutic Areas), and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World) - Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    March 2021

  • Pages
    235

  • View Count
    3543

Example Insights

Biopharmaceutical-Contract-Research-Organizations-Market-Context Biopharmaceutical-Contract-Research-Organizations-Market-Landscape Biopharmaceutical-Contract-Research-Organizations-Market-Distribution
Biopharmaceutical-Contract-Research-Organizations-Market-Comparison-of-Key-Parameters Biopharmaceutical-Contract-Research-Organizations-Market-Partnerships-and-Collaborations Biopharmaceutical-Contract-Research-Organizations-Market-Mergers-and-Acquisitions
Biopharmaceutical-Contract-Research-Organizations-Market-Distribution-by-Therapeutic-Area    

 

Overview

Given the various advantages of biologics, such as high specificity for their intended molecular targets, ability to treat a myriad of disease indications, and patient friendly toxicity profiles, the demand for such interventions is high. In 2020 alone, more than 20 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapies) were approved in the US. Amidst the COVID-19 pandemic, the biopharmaceutical industry has witnessed considerable growth, with several stakeholders actively engaged in the development of multiple vaccine candidates, some of which have received emergency use authorizations against the novel coronavirus strain. However, it is a well-known fact that the development and clinical evaluation of biologics is both challenging and cost intensive, and requires advanced product development expertise and bioprocessing technologies. Therefore, many innovators in the biopharmaceutical industry are opting to outsource their drug discovery and clinical research operations to capable contract service providers.

Contract research organizations (CROs) have the necessary capabilities and experience to expertly support biopharmaceutical R&D projects. Being well-aware of the nuances of drug design and development, such organizations have long been assisting biologics developers to navigate through process-related complexities and stringent regulatory environments, across different geographies. Several big pharma players, with multifarious product development programs, are increasingly engaging with third party research entities to reduce the strain on their internal R&D infrastructure. In fact, it is estimated that big pharma players presently outsource close to 45% of their internal R&D operations to CROs. In the past few years, several niche CROs, claiming to offer services for the development of specialty biologics, have been established, and are gradually being acquired by larger entities that are trying to consolidate their presence amidst the growing competition in this space. The contract research services segment is considered to be an indispensable part of the overall biopharmaceutical market. As more developers opt to outsource various aspects of their business processes, we anticipate the biologics contract research services market to grow at a steady pace in the coming years.

Scope of the Report

The “Biopharmaceutical CROs Market, 2021-2030: Distribution by Type of Biologic (Vaccines, Cell Therapy, Gene Therapy, Antibodies, Recombinant Proteins / Peptides, and Others), Scale of Operation (Clinical and Preclinical), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, and Other Therapeutic Areas), and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World)” report features an extensive study of the current market landscape and the likely future potential of the biopharmaceutical CROs market, over the next decade. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed review of the overall landscape of the biopharmaceutical services market, highlighting the contributions of CROs, along with information on their year of establishment, company size, location of headquarters, types of biologics manufactured (vaccines, cell therapies, gene therapies, antibodies, recombinant proteins / peptides, vectors, biosimilars and others), scale of operation (clinical and preclinical) and types of services offered (including [A] clinical services (trial management services, clinical data management, safety and pharmacovigilance services, regulatory services, consulting services and other clinical services) and [B] preclinical services (toxicology studies, in vivo studies, safety studies, PK / ADME and other bioanalytical studies, consulting services, regulatory services, other preclinical services). 
  • A benchmark analysis of the various players engaged in this domain. It highlights the capabilities of companies (in terms of their expertise across various services related to the development of biopharmaceuticals) and allows players to compare their existing capabilities within and beyond their peer groups to identify opportunities to gain a competitive edge.  
  • A detailed analysis of the various partnerships inked between CROs offering biopharmaceutical related services. It includes a brief description of the various types of partnerships models (such as outsourcing agreements, licensing agreements, and service alliances) that have been adopted by stakeholders engaged in this domain, since 2016. 
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2016-2020. It is worth mentioning that the data captured during our research was analyzed based on several parameters.
  • A detailed acquisition target analysis, taking into consideration the historical trend of the activity of players that have acquired other firms since 2016, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • A proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
  • A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.
  • Elaborate profiles of prominent CROs engaged in offering biopharmaceutical related services. Each company profile features a brief overview of the company, along with information on their year of establishment, number of employees, location of headquarters and key executives, financial details (if available), service portfolio, recent developments and an informed future outlook.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the biopharmaceutical CROs market over the coming decade. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of biologic (vaccines, cell therapies, gene therapies antibodies, recombinant proteins / peptides, and others), [B] scale of operation (clinical and preclinical), [C] target therapeutic area (oncological disorders, cardiovascular disorders, inflammatory disorders, neurological disorders, and other therapeutic areas) and [D] key geographical region (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).  In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified. 

Key Questions Answered

  • Who are the key players engaged in offering research related services for biopharmaceuticals?
  • Which business models are commonly adopted by biopharmaceutical companies for the outsourcing their research and development operations?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • What are the key value drivers of the merger and acquisition activity observed within this domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to biopharmaceutical related research services?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the biopharmaceutical CROs market and its likely evolution in the mid-long term.

Chapter 3 provides a general introduction to CROs, featuring insights on the historical evolution of such organizations, legacy and contemporary trends in outsourcing activity. It further includes a brief introduction to the concept of CROs, featuring a discussion on the historical evolution of contract research services market in this domain. Additionally, it highlights details related to the various types of services offered by different CROs. Further, the chapter includes the advantages and risks related to partnering with contract service providers.

Chapter 4 features a detailed discussion on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing biologics. In addition, it includes information on the various factors that drive sponsors towards outsourcing and key parameters that sponsors must consider while choosing CROs across each phase of the drug development process.

Chapter 5 provides a detailed review of the overall landscape of the biopharmaceutical services market, highlighting the contributions of CROs, along with the information on year of establishment, company size, location of headquarters, A detailed assessment of the overall market landscape of about 200 CROs offering biopharmaceuticals based on a number of relevant parameters, such as  types of biologics (vaccines, cell therapies, gene therapies antibodies, recombinant proteins / peptides, vectors, biosimilars and others), scale of operation (clinical and preclinical) and types of services offered including [A] clinical services (trial management services, clinical data management, safety and pharmacovigilance services, regulatory services, consulting services and other clinical services) and [B] preclinical services (toxicology studies, in vivo studies, safety studies, PK / ADME and other bioanalytical Studies, consulting services, regulatory services, other preclinical services).  

Chapter 6 features elaborate profiles of prominent CROs engaged in offering biopharmaceutical related services. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team. It also includes details of their financial details / information (if available), service portfolio, and recent developments and an informed future outlook.

Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies in terms of their expertise across various services related to the development of biopharmaceuticals. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.  

Chapter 8 features an analysis of the various partnerships inked between CROs offering biopharmaceutical related services, which have been established. It includes a brief description on various types of partnerships models (such as outsourcing agreements, licensing agreements, and service alliances) that have been employed by stakeholders in this domain since 2016.

Chapter 9 presents insights from a detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2016-2020. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year, type of acquisition, geographical location of the companies, and types of biologics.

Chapter 10 features a proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

Chapter 11 features a comprehensive market forecast analysis, highlighting the likely growth of cell and gene therapy CROs market, for the time period 2021-2030. In order to provide details on the future outlook, our projections have been segmented on the basis of [A] types of biologics (vaccines, cell therapies, gene therapies, antibodies, recombinant proteins / peptides and others) [B] scale of operation (clinical and preclinical), [C] target therapeutic areas (oncological disorders, cardiovascular disorders, inflammatory disorders, neurological disorders, and other therapeutic areas) and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).

Chapter 12 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall biopharmaceutical research services industry.

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of survey transcript(s) of the discussions that were held key stakeholders in the industry. 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report. 

Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report. 

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3 Introduction
3.1. Chapter Overview
3.2. Overview of Biologics
3.2.1. Types of Biologics

3.3. Overview of Contract Research Organizations (CROs)
3.4. Evolution of CROs
3.5. Classification of CROs
3.6. Services Offered by CROs
3.7. Advantages of Outsourcing Operations to CROs
3.8. Risks Associated with Outsourcing Operations to CROs

4. GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing Biologics Research

4.3. Models of Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Model

4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach

4.5. Selecting a CRO Partner
4.5.1. Key Considerations for Outsourcing Biologics-related Operations

4.6. Role of CROs in the Drug Development Process
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services

4.7. Conclusion

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Biopharmaceutical CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
5.2.2. Analysis by Scale of Operation

5.3. Preclinical Biopharmaceutical CROs
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size 
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Biologic 
5.3.5. Analysis by Type of Services Offered 

5.4. Clinical Biopharmaceutical CROs
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Analysis by Type of Biologics
5.4.5. Analysis by Type of Services Offered

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Biocon
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Services Portfolio
6.2.4. Future Outlook

6.3. Covance
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Financial Information
6.3.4. Future Outlook

6.4. ICON
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Service Portfolio
6.4.4. Future Outlook

6.5. Medpace
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Future Outlook

6.6. Pharmaron
6.6.1. Company Overview
6.6.2. Services Portfolio
6.6.3. Future Outlook

6.7. PPD
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Financial Information
6.7.4. Future Outlook

6.8. PRA Health Sciences
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Service Portfolio
6.8.4. Future Outlook

6.9. Syneos Health
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Services Portfolio
6.9.4. Future Outlook

6.10. Vimta Labs
6.10.1. Company Overview
6.10.2. Services Portfolio
6.10.3. Financial Information
6.10.4. Future Outlook

6.11. WuXi AppTec
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Service Portfolio
6.11.4. Future Outlook

7. BENCHMARK ANALYSIS
7.1. Chapter Overview 
7.2. Methodology 
7.3. Benchmark Analysis: Peer Groups 
7.3.1. Peer Group I 
7.3.2. Peer Group II 
7.3.3. Peer Group III 
7.3.4. Peer Group IV 
7.3.5. Peer Group V
7.3.5. Peer Group VI
7.3.5. Peer Group VII
7.3.5. Peer Group VIII

8. PARTNERSHIPS AND COLLABORATIONS 
8.1. Chapter Overview
8.2. Partnership Models

8.3. Biopharmaceutical CROs: Recent Partnerships and Collaborations 
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership Model
8.3.2.1. Analysis by Year of Partnership and Type of Partnership Model

8.3.3. Most Active Players: Analysis by Number of Partnerships
8.3.4. Analysis by Scale of Operation
8.3.5. Analysis by Geography
8.3.5.1. Country-wise Analysis
8.3.5.2. Intercontinental and Intracontinental Agreements

9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models

9.3. Biopharmaceutical CROs: Mergers and Acquisitions
9.3.1. Analysis by Year of Acquisition
9.3.2. Analysis by Type of Collaboration
9.3.3. Analysis by Geography
9.3.3.1. Continent-wise Distribution
9.3.3.2. Country-wise Distribution
9.3.4 Ownership Change Matrix
9.3.5. Most Active Acquirers: Analysis by Number of Acquisitions

9.4. Distribution by Key Value Drivers
9.4.1 Analysis by Key Value Drivers
9.4.2 Analysis by Key Value Drivers and Year of Acquisitions
9.5. Valuation Analysis: Acquisition Deal Multiples

10. ATTRACTIVENESS COMPETATIVENESS MATRIX
10.1. Chapter Overview

10.2. AC Matrix: Overview
10.2.1. Strong Business Segment
10.2.2. Average Business Segment
10.2.3. Weak Business Segment

10.3. Analytical Methodology
10.4. AC Matrix: Contract Manufacturing Scenario in North America
10.5. AC Matrix: Contract Manufacturing Scenario in Europe
10.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions

11.3. Global Biopharmaceutical CROs Market
11.3.1. Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
11.3.2. Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
11.3.3. Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
11.3.4. Global Biopharmaceutical CROs Market: Distribution by Geography

11.4. Biopharmaceutical CROs Market in North America
11.4.1. Biopharmaceutical CROs Market in North America: Distribution by Therapeutic Area
11.4.1.1. Biopharmaceutical CROs Market for Oncological Disorders in North America, 20212030
11.4.1.2. Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, 2021-2030
11.4.1.3. Biopharmaceutical CROs Market for Inflammatory Disorders in North America, 2021-2030
11.4.1.4. Biopharmaceutical CROs Market for Neurological Disorders in North America, 2021-2030
11.4.1.5. Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, 2021-2030
11.4.2. Biopharmaceutical CROs Market in North America: Distribution by Scale of Operation
11.4.2.1. Biopharmaceutical CROs Market for Preclinical Operations in North America, 2021-2030
11.4.2.2. Biopharmaceutical CROs Market for Clinical Operations in North America, 2021-2030

11.5. Biopharmaceutical CRO Services Market in Europe
11.5.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Europe
11.5.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Europe, 2021-2030
11.5.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Europe, 2021-2030
11.5.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Europe, 2021-2030
11.5.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Europe, 2021-2030
11.6.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Europe, 2021-2030

11.5.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Europe
11.5.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Europe, 2021-2030
11.5.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Europe, 2021-2030

11.6. Biopharmaceutical CRO Services Market in Asia-Pacific
11.6.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Asia-Pacific
11.6.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Asia-Pacific, 2020-2030
11.6.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030
11.6.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Asia-Pacific, 2020-2030
11.6.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Asia-Pacific, 2020-2030
11.6.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030
11.6.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Asia-Pacific
11.6.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Asia-Pacific, 2020-2030
11.6.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Asia-Pacific, 2020-2030

11.7. Biopharmaceutical CRO Services Market in Latin America
11.8. Biopharmaceutical CRO Services Market in Middle East North America

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors

13. CONCLUDING REMARKS
13.1. Chapter Overview

14. SURVEY TRANSCRIPTS

15. APPENDIX I: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Types of Biologics
Figure 3.2 Stages of the Drug Development Process
Figure 3.3 Commonly Offered Services by CROs
Figure 3.4 Advantages of Outsourcing Operations to CROs
Figure 3.5 Risks Associated with Outsourcing Operations to CROs
Figure 4.1 Guiding Models for Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance / Outcome based Business Model
Figure 4.4 Steps to Consider before Outsourcing
Figure 4.5 Key Considerations while Selecting a CRO Partner
Figure 4.6 Role of CROs in the Drug Development Process
Figure 5.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 5.2 Biopharmaceutical CROs: Distribution by Scale of Operation
Figure 5.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Figure 5.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Figure 5.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Figure 5.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Figure 5.7 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Figure 5.8 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Figure 5.9 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 5.10 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Figure 5.11 Biopharmaceutical Clinical CROs: Distribution by Company Size
Figure 5.12 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Figure 5.13 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Figure 5.14 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Figure 5.15 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Figure 5.16 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 6.1 Biocon: Annual Services Revenues, 2016 – 9M 2020 (INR Billion)
Figure 6.2 Biocon: Service Portfolio
Figure 6.3 Covance: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.4 Covance: Service Portfolio
Figure 6.5 ICON: Annual Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.6 ICON: Service Portfolio
Figure 6.7 Medpace: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.8 Medpace: Service Portfolio
Figure 6.9 Medpace: Regulatory Affair Capabilities
Figure 6.10 Pharmaron: Service Portfolio
Figure 6.11 PPD: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.12 PPD: Service Portfolio
Figure 6.13 PRA Health Sciences: Annual Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.14 PRA Health Sciences: Service Portfolio
Figure 6.15 Syneos Health: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.16 Syneos Health: Service Portfolio
Figure 6.17 Vimta Labs: Annual Service Revenues, 2016 – 9M 2020 (INR Billion)
Figure 6.18 Vimta Labs: Service Portfolio
Figure 6.19 WuXi App Tec: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.20 WuXi App Tec: Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution by Company Size and Location of Headquarters
Figure 7.2 Benchmark Analysis: Peer Group I
Figure 7.3 Benchmark Analysis: Peer Group II
Figure 7.4 Benchmark Analysis: Peer Group III
Figure 7.5 Benchmark Analysis: Peer Group IV
Figure 7.6 Benchmark Analysis: Peer Group V
Figure 7.7 Benchmark Analysis: Peer Group VI
Figure 7.8 Benchmark Analysis: Peer Group VII
Figure 7.9 Benchmark Analysis: Peer Group VIII
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership Model
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
Figure 8.4 Most Active Players: Distribution by Number of Partnerships
Figure 8.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 8.6 Partnerships and Collaborations: Distribution by Geography
Figure 8.7 Partnerships and Collaborations: Country-Wise Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (2016- 2020)
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Figure 9.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
Figure 9.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 9.5 Mergers and Acquisitions: Region-wise Distribution
Figure 9.6 Mergers and Acquisitions: Country-wise Distribution
Figure 9.7 Mergers and Acquisitions: Ownership Change Matrix
Figure 9.8 Mergers and Acquisitions: Key Value Drivers
Figure 9.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 9.10 Mergers and Acquisitions: Deal Multiples Based on Revenue
Figure 9.11 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
Figure 10.1. AC Matrix: Pictorial Representation
Figure 10.2. AC Matrix: Positioning of Different Biologics in North America
Figure 10.3. AC Matrix: Positioning of Different Biologics in Europe
Figure 10.4. AC Matrix: Positioning of Different Biologics in Asia Pacific
Figure 11.1 Biopharmaceutical CROs: Market Forecast Methodology
Figure 11.2 Global Biopharmaceutical CROs Market, 2021-2030
Figure 11.3 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics, 2021 and 2030
Figure 11.4 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area, 2021 and 2030
Figure 11.5 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation, 2021 and 2030
Figure 11.6 Global Biopharmaceutical CROs Market: Distribution by Geography, 2021 and 2030
Figure 11.7 Biopharmaceutical CROs Market in North America, 2021-2030 (USD Million)
Figure 11.8 Biopharmaceutical CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 11.9 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 11.10 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Figure 11.11 Biopharmaceutical CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 11.12 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 11.13 Biopharmaceutical CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 11.14 Biopharmaceutical CROs Market for Clinical Operations in North America, 2021-2030 (USD Million
Figure 11.15 Biopharmaceutical CROs Market in Europe, 2021-2030 (USD Million)
Figure 11.16 Biopharmaceutical CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 11.17 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 11.18 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Figure 11.19 Biopharmaceutical CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 11.20 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 11.21 Biopharmaceutical CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 11.22 Biopharmaceutical CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 11.23 Biopharmaceutical CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.24 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.25 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.26 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.27 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.28 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.29 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.30 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.31 Biopharmaceutical CROs Market in Latin America, 2021-2030 (USD Million)
Figure 11.32 Biopharmaceutical CROs Market in Middle East North Africa, 2021-2030 (USD Million)
Figure 11.33 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 12.1 Biopharmaceutical CROs SWOT Analysis: Overview
Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1 Concluding Remarks: Current Market Landscape for Preclinical Biopharmaceutical CROs
Figure 13.2 Concluding Remarks: Current Market Landscape for Clinical Biopharmaceutical CROs
Figure 13.3 Concluding Remarks: Recent Partnerships
Figure 13.4 Concluding Remarks: Mergers and Acquisitions
Figure 13.5 Concluding Remarks: Clinical Trial Analysis
Figure 13.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 Attributes of Transactional Outsourcing Based Business Model
Table 4.2 Comparison of Key Factors Considered by Biologic Developers for Selecting a CRO Partner: Harvey Ball Analysis
Table 5.1 Biopharmaceutical CROs: Information on Year of Establishment, Location of Headquarters, Company Size and Types of Biologics
Table 5.2 Biopharmaceutical Preclinical CROs: Information on Types of Services Offered
Table 5.3 Biopharmaceutical Clinical CROs: Information on Types of Services Offered
Table 6.1 Biocon: Company Overview
Table 6.2 Biocon: Future Outlook
Table 6.3 Covance: Company Overview
Table 6.4 Covance: Future Outlook
Table 6.5 ICON: Company Overview
Table 6.6 ICON: Future Outlook
Table 6.7 Medpace: Company Overview
Table 6.8 Medpace: Future Outlook
Table 6.9 Pharmaron: Company Overview
Table 6.10 Pharmaron: Future Outlook
Table 6.11 PPD: Company Overview
Table 6.12 PPD: Future Outlook
Table 6.13 PRA Health Sciences: Company Overview
Table 6.14 PRA Health Sciences: Future Outlook
Table 6.15 Syneos Health: Company Overview
Table 6.16 Syneos Health: Future Outlook
Table 6.17 VIMTA Labs: Company Overview
Table 6.18 WuXi App-Tec: Company Overview
Table 6.19 WuXi App Tec: Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 Partnerships and Collaborations: List of Agreements, 2016-2021
Table 9.1 Mergers and Acquisitions: List of Mergers / Acquisitions, 2016 - 2020
Table 9.2 Mergers and Acquisitions: Information on Key Value Drivers, 2016- 2020
Table 9.3 Mergers and Acquisitions: Deal Multiples, 2016- 2020
Table 15.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 15.2 Biopharmaceutical CROs: Distribution by Scale of Operation
Table 15.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Table 15.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Table 15.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Table 15.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Table 15.8 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Table 15.9 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Table 15.10 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types Services Offered
Table 15.11 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Table 15.12 Biopharmaceutical Clinical CROs: Distribution by Company Size
Table 15.13 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Table 15.14 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Table 15.15 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Table 15.16 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Table 15.17 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
Table 15.18 Biocon: Annual Service Revenues, 2016 – 9M 2020 (INR Billion)
Table 15.19 Covance: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.20 ICON: Annual Revenues, 2016 - 9M 2020 (USD Billion)
Table 15.21 Medpace: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.22 PPD: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.23 PRA Health Sciences: Annual Revenues, 2016 - 9M 2020 (USD Billion)
Table 15.24 Syneos: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.25 Vimta Labs: Annual Service Revenues, 2016 – 9M 2020 (INR Billion)
Table 15.26 WuXi AppTec: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.27 Partnerships and Collaborations: Distribution by Year of Partnership
Table 15.28 Partnerships and Collaborations: Distribution by Type of Partnership Model
Table 15.29 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
Table 15.30 Most Active Players: Distribution by Number of Partnerships
Table 15.31 Partnerships and Collaborations: Distribution by Scale of Operation
Table 15.32 Partnerships and Collaborations: Distribution by Geography
Table 15.33 Partnerships and Collaborations: Country-Wise Distribution
Table 15.34 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.35 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (2016- 2020)
Table 15.36 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Table 15.37 Mergers and Acquisitions: Distribution by Year and Type of Agreement
Table 15.38 Mergers and Acquisitions: Continent-wise Distribution
Table 15.39 Mergers and Acquisitions: Continent-wise Distribution
Table 15.40 Mergers and Acquisitions: Country-wise Distribution
Table 15.41 Mergers and Acquisitions: Ownership Change Matrix
Table 15.42 Mergers and Acquisitions: Key Value Drivers
Table 15.43 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 15.44 Mergers and Acquisitions: Deal Multiples Based on Revenue
Table 15.45 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
Table 15.46 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics, 2021 and 2030
Table 15.47 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area, 2021 and 2030
Table 15.48 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation, 2021 and 2030
Table 15.49 Global Biopharmaceutical CROs Market: Distribution by Geography, 2021 and 2030
Table 15.50 Biopharmaceutical CROs Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.51 Biopharmaceutical CROs Market for Oncological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.52 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.53 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.54 Biopharmaceutical CROs Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.55 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.56 Biopharmaceutical CROs Market for Preclinical Operations in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.57 Biopharmaceutical CROs Market for Clinical Operations in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.58 Biopharmaceutical CROs Market in Europe, 2021-2030 (USD Million)
Table 15.59 Biopharmaceutical CROs Market for Oncological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.60 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 15.61 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.62 Biopharmaceutical CROs Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.63 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.64 Biopharmaceutical CROs Market for Preclinical Operations in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.65 Biopharmaceutical CROs Market for Clinical Operations in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.66 Biopharmaceutical CROs Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.67 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.68 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.69 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.70 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.71 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.72 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.73 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.74 Biopharmaceutical CROs Market for Preclinical Operations in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.75 Biopharmaceutical CROs Market for Preclinical Operations in Middle East North Africa, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.76 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 4Clinics
  2. Abiogenesis Clinpharm
  3. Accelovance
  4. Accelsiors
  5. Accutest
  6. acromion
  7. Advanced Clinical
  8. Aesculape CRO 
  9. Alderley Analytical
  10. Alliance Pharma
  11. Allied Clinical Management
  12. Almirall
  13. Altasciences
  14. Amarex Clinical Research
  15. AOBiome
  16. APEIRON Biologics
  17. Aqlivia
  18. ARVYS Proteins
  19. AstraZeneca
  20. Auriga Research
  21. Aurigon
  22. Avania
  23. Beaufort
  24. Biocon
  25. BioGeneration Ventures
  26. Biomere
  27. Bioneeds
  28. Biotrend
  29. Bit Bio
  30. BrainStorm Cell Therapeutics
  31. BSL Bioservice
  32. BTS Research
  33. Catalyst Clinical Services
  34. CATO SMS
  35. Celgene
  36. CellTrans
  37. Charles River Laboratories
  38. ChemPartner
  39. Cliantha
  40. Clinartis
  41. ClinChoice
  42. Clindataceutics 
  43. Clinexa Life Sciences
  44. Clinfomatrix
  45. Clinipace
  46. ClinSmart
  47. Cmed
  48. Cobridge
  49. COD Research
  50. CombiGene
  51. Confidence Pharmaceutical Research
  52. Covance
  53. CPL Biologicals
  54. CR2O
  55. CRC Oncology
  56. Crown Bioscience
  57. CSSi LifeSciences
  58. CTI
  59. Cynbiose
  60. Diamond Pharma Services
  61. DiscGenics
  62. dMed Biopharmaceutical
  63. DP Clinical
  64. DuPage Medical
  65. EMMES
  66. Ergomed
  67. ethica CRO
  68. Eubiologics
  69. Everest Clinical Research
  70. Evotec
  71. Excelya
  72. Fast-Track Drugs and Biologics
  73. FGK Clinical Research
  74. FHI Clinical
  75. Fios Genomics
  76. Forbion
  77. Frontage
  78. Geistek Pharma
  79. Genelife Clinical Research
  80. GeneMedicine
  81. Generic Specialties
  82. Genesis Biotechnology
  83. Geneticist
  84. GeneWerk
  85. GenoSafe
  86. Genprex
  87. Gladstone
  88. Guosa Life Sciences
  89. GVK BIO
  90. Harbour BioMed
  91. Heidelberg Pharma
  92. Hubrecht Organoid Technology
  93. ICON
  94. Immunicum
  95. ImmunoPrecise Antibodies
  96. ImQuest BioSciences
  97. Innovaderm
  98. Insignia Clinical Services
  99. InteRNA Technologies
  100. International Vaccine Institute
  101. IQVIA
  102. IRBM
  103. Iris Pharma
  104. Johnson County Clin-Trials
  105. JSR Life Sciences
  106. KCR
  107. Klinar CRO
  108. Lambda Therapeutic Research
  109. LatinaBA
  110. Lava Therapeutics
  111. Linical
  112. LINK Medical
  113. Lonza
  114. Lovelace Biomedical
  115. LSK Global Pharma Service
  116. Magenta Therapeutics
  117. MCRA
  118. Medidee
  119. Medpace
  120. MetabAxis
  121. Milner Therapeutics Institute
  122. Mithra Biotechnology
  123. MKR Clinical Research Consultants
  124. MTZ Clinical Research
  125. NBE Therapeutics
  126. Neozene
  127. NetValue BioConsulting
  128. Nexelis
  129. NEXT Oncology
  130. Noble Life Sciences
  131. Nutrasource
  132. Nuvisan
  133. OncoBay Clinical
  134. Open Orphan
  135. Oxford BioTherapeutics
  136. Palm Beach CRO
  137. Pepgra
  138. Pfizer
  139. Pharma Models
  140. Pharmaron
  141. Pharmaseed
  142. PharmOut
  143. Phoenix Clinical Research
  144. PPD
  145. PRA Health Sciences
  146. PRC Clinical
  147. Precision For Medicine
  148. Prestige BioPharma
  149. Prince William Science Accelerator
  150. Prodia the CRO
  151. ProRelix Research
  152. PSN Research
  153. QAscent Research Solutions
  154. QPS
  155. Q-Trials
  156. Quad-C Management
  157. QUADRO CRO
  158. Quality by Design (QbD)
  159. Quanticate
  160. Radyus Research
  161. RCT
  162. Renova Therapeutics
  163. Rho
  164. RiboBio
  165. RTI Health Solutions 
  166. RTI International
  167. SanaClis
  168. Sandoz
  169. Sanyou Biopharmaceuticals
  170. SBH Sciences
  171. SCiAN Services
  172. Scope International
  173. Secarna Pharmaceuticals
  174. SEKISUI XenoTech
  175. Sernova
  176. Simbec-Orion
  177. SMS-oncology
  178. STATKING Clinical Services
  179. Strategic Preclinical Product Development (S2PD)
  180. Svar Life Science
  181. Symbion Research International
  182. Symeres
  183. Syneos Health
  184. Takeda
  185. Technical Resources International
  186. The Geneva Foundation
  187. The Smerud Medical Research
  188. Therapeutics
  189. Tonic Bioventures
  190. Tranz-Life
  191. VaxTrials
  192. Veeda Clinical Research
  193. Veristat
  194. Vimta Labs
  195. Virginia Contract Research Organization
  196. VisMederi
  197. Vium
  198. Vivotecnia
  199. Washington Biotechnology
  200. WCCT
  201. Worldwide Clinical Trials
  202. WuXi AppTec
  203. Xcene Research

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com